Protagonist Therapeutics Inc. held its Annual Meeting of Stockholders on April 29, 2025. The stockholders voted on three proposals. The election of two Class III director nominees, Harold E. Selick, Ph.D., and Bryan Giraudo, was approved. The compensation of the company's named executive officers was approved on a non-binding, advisory basis. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. No other matters were submitted for stockholder action.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.